Fig. 7

Schematic diagram for anti-metastatic effect of GV1001. GV1001-stimulated GnRHR/Gαs/cAMP pathway simultaneously causes both the activation of AR and the inactivation of YAP via phosphorylation of Ser-81 AR and Ser-127 YAP1, respectively. NKX3.1 upregulation by AR activation and YAP1 degradation in GV1001-treated PCa cells switches AR-YAP1 binding to AR-NKX3.1 binding